Ocugen Inc (NASDAQ:OCGN) shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.
Ocugen says the company intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN.
Ocugen is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.
See Also: Why This Wheat-Focused ETF Is Suddenly On The Radar Of Retail Investors
Ocugen has a 52-week high of $17.65 and a 52-week low of $2.87.
